



Alpa Laboratories Ltd.

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444

Email : mail@alpalabs.in

CIN L85195MP1988PLC004446

3rd November, 2018

To,
Listing Department,
BSE Limited.
Rotunda Building, P J Towers
Dalal Street, Fort,
Mumbai – 400 001

To,
Listing Department,
National Stock Exchange of India Limited.
'Exchange Plaza', C-1, Block G,
Bandra - Kurla Complex,
Bandra (E), Mumbai – 400 051

Subject: Outcome of Board Meeting under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Reference: Scrip Code: ALPA ; ISIN: INE385I01010

Dear Sir/ Madam,

We refer to our letter dated 23rd October, 2018 in relation to the intimation of board meeting; this is to inform you that the Board of Directors of the Company at its meeting held today at 4.00 p.m. at registered office of the Company situated at 33/2, A.B. Road Pigdamber Rao, Indore MP 453446 IN. The Board inter-alia has approved the following matter:

1 Approval of the Un-audited Standalone Financial Results Result of the Company along with Limited Review Report from the Statutory Auditor for quarter & half year ended on 30th September, 2018.

This is for the information and record of the exchange and members thereof;

You are requested to take the same on records.

Thanking you,

Yours Faithfully

For ALPA LABORATORIES LIMITED

For ALPA LABORATORIES LIMITED

MEGHA NEEMA

MEGHA NEEMA
COMPANY SECRETARY AND COMPLIANCE OFFICER

Company Secretary

| Particulars | Standalone Results | | | | | |
|--|--------------------|-----------------|-----------------|------------------------------------|------------------------------------|-----------------------|
| | Quarter Ended | | | 6 Month Ended | | Year Ended |
| | Sep-18 | Jun-18 | Sep-17 | For Six Month Ending On 30.09.2018 | For Six Month Ending On 30.09.2017 | Year Ended March 2018 |
| | Unaudited | | | | | Audited |
| 1. Income | | | | | | |
| a) Revenue from operations | 1,590.77 | 1,700.87 | 1,558.76 | 3,291.64 | 2,678.16 | 6,226.82 |
| b) Other Income | 95.69 | 110.14 | 114.28 | 206.92 | 263.38 | 451.44 |
| 1. Total income from operations (net) (a+b) | 1,686.45 | 1,811.01 | 1,673.04 | 3,498.56 | 2,941.54 | 6,678.26 |
| 2. Expenses | | | | | | |
| a) Cost of materials consumed | 1,173.22 | 856.25 | 796.76 | 2,029.56 | 1,477.45 | 3,304.56 |
| b) Purchases of stock-in-trade | 17.50 | 20.67 | 49.48 | 38.17 | 135.56 | 226.66 |
| c) Changes in inventories of fin. goods, stock-in-pro. & stock- | (263.17) | 136.11 | 133.48 | (127.06) | 18.68 | 31.07 |
| d) Employee benefits expenses | 274.44 | 262.11 | 249.09 | 536.65 | 489.44 | 1,025.56 |
| e) Finance costs | 20.49 | 18.13 | 36.85 | 39.73 | 61.27 | 107.15 |
| f) Depreciation and amortization expenses | 28.35 | 28.35 | 25.07 | 55.98 | 47.87 | 112.89 |
| g) Other expenses | | | | | | |
| Manufacturing & Operating | 102.85 | 99.41 | 84.51 | 202.25 | 181.33 | 357.32 |
| (Stores and spares consumed, power & fuel, | | | | | | |
| Others | 270.43 | 205.30 | 65.78 | 484.50 | 144.95 | 853.32 |
| Total expenses | 1,624.10 | 1,626.33 | 1,441.02 | 3,259.79 | 2,556.55 | 6,018.53 |
| 3. Profit /(Loss) before exceptional items and tax (1-2) | 62.35 | 184.67 | 232.03 | 238.78 | 384.99 | 659.73 |
| 4. Exceptional Items | - | - | - | - | - | - |
| 5. Profit/ Loss(-) before tax (3+/-4) | 62.35 | 184.67 | 232.03 | 238.78 | 384.99 | 659.73 |
| 6. Tax (Expenses)/ Benefit | | | | | | |
| Current tax | - | 18.73 | - | 18.73 | - | (188.93) |
| Deffered tax | - | - | - | - | - | 10.49 |
| 7. Profit/ Loss(-) for the period (5-/+6) | 62.35 | 203.40 | 232.03 | 257.51 | 384.99 | 481.29 |
| 8. Other Comprehensive Income | | | | | | |
| (i) (a) Items that will not be reclassified to profit or loss | - | - | - | - | - | - |
| (b) Tax expense/(benefit) on items that will not be reclassified to profit or loss | - | - | - | - | - | - |
| (ii) (a) Items that will be reclassified to profit & loss | - | - | - | - | - | - |
| (b) Tax expense/(benefit) on items that will be reclassified to profit or loss | - | - | - | - | - | - |
| Total Other comprehensive (loss)/ income (net of tax) | - | - | - | - | - | - |
| 9. Total comprehensive income for the period (16+17) | 62.35 | 203.40 | 232.03 | 257.51 | 384.99 | 481.29 |
| 10. Paid-up equity share capital (Face Value `10 Each) | 2,104.06 | 2,104.06 | 2,104.06 | 2,104.06 | 2,104.06 | 2,104.06 |
| 11. Other equity (excluding revaluation reserve) | | | | | | 8,223.49 |
| 12. Debenture Redemption Reserve | | | | | | |
| 13. Basic and Diluted Earnings per share after extraordinary items ` (not annualized) | 0.30 | 0.97 | 1.10 | 1.22 | 1.83 | 2.29 |

Notes -

1. The above results have been subjected to Limited Review by the Statutory Auditors, reviewed by Board Audit Committee and have been approved by the Board of Directors at its meeting today.

2. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies (Indian accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Accounting Rules, 2016

3. The Company is operating in the single segment of Drugs & Chemicals.

4. The Provision for Tax may not have been made for the partial/ unaudited periods.

5. The Figures of Previous Year/ Periods may have been regrouped/ reclassified wherever necessary.

6. During the year under review, it has been noticed that the scheme of Merger of Norfolk Mercantile Private Limited with Alpa Laboratories Limited had been sanctioned by the Hon'ble Bench of NCLT, Ahmedabad vide order No. 92/NCLT/AHM/2018 dated 10.09.2018 subject to the sanction of the scheme of by the Hon'ble Bench of NCLT, Mumbai.



| Particulars | Sep-18 | Mar-18 |
|---|------------------|------------------|
| | Unaudited | Audited |
| ASSETS | | |
| Non-current assets | | |
| (a) Property Plant and Equipment | 571.60 | 602.58 |
| (b) Capital Work-in-progress | 8.46 | - |
| (c) Investments in subsidiaries, associates and joint venture | 1,074.29 | 1,078.61 |
| (d) Financial Assets | | |
| (i) Investment | 1,460.54 | 1,291.54 |
| (e) Deferred tax assets (net) | 76.13 | 76.13 |
| Sub-total - Non-current assets | 3,191.02 | 3,048.86 |
| Current Assets | | |
| (a) Inventories | 1,761.24 | 1,372.30 |
| (b) Financial Assets | | |
| (i) Investment | 2,441.36 | 1,770.79 |
| (ii) Trade receivables | 2,813.48 | 2,544.16 |
| (iii) Cash and Cash Equivalents | 4.60 | 13.50 |
| (iv) Bank Balances other than (iii) above | 1,419.99 | 2,115.06 |
| (v) Short term loans & advances | 396.75 | 468.73 |
| (vi) Others | 132.57 | 114.33 |
| (c) Current Tax Assets (Net) | - | 146.93 |
| (d) Other current assets | 1,293.46 | 1,058.99 |
| Sub-total - Current assets | 10,263.45 | 9,604.80 |
| TOTAL - ASSETS | 13,454.47 | 12,653.66 |
| EQUITY AND LIABILITIES | | |
| Equity | | |
| (a) Equity Share capital | 2,104.06 | 2,104.06 |
| (b) Other Equity | 8,474.48 | 8,216.88 |
| Sub-total - Equity | 10,578.54 | 10,320.94 |
| Liabilities | | |
| Non-current liabilities | | |
| (a) Financial Liabilities | | |
| (i) Borrowings | 70.89 | 61.37 |
| Sub-total - Non-current liabilities | 70.89 | 61.37 |
| Current liabilities | | |
| (a) Financial Liabilities | | |
| (i) Borrowings | 878.77 | 517.80 |
| (ii) Trade Payables | 1,417.61 | 1,268.49 |
| (iii) Other Financial Liabilities | 121.74 | 135.99 |
| (b) Other Current Liabilities | 310.35 | 242.43 |
| (c) Provisions | 76.56 | 106.64 |
| Sub-total - Current liabilities | 2,805.03 | 2,271.35 |
| TOTAL - EQUITY AND LIABILITIES | 13,454.47 | 12,653.66 |





**INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON
STANDALONE QUARTERLY FINANCIAL RESULTS PURSUANT TO
REGULATIONS 33 OF THE SEBI (LODR),2015.**

TO THE BOARD OF DIRECTORS ALPA LABORATORIES LIMITED

1. We have reviewed the accompanying standalone statement of unaudited financial results of Alpa Laboratories Limited **for the quarter ended 30th September, 2018**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the standard on Review Engagement (SRE) 2410 Review of Interim Financial Information issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material mis-statement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than audit. We have not performed an audit and accordingly we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited results which is prepared in accordance with applicable accounting standards and other recognised accounting practices and policies, has not disclosed any information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations,2015 including the manner in which is to be disclosed, or that it contains any material misstatement.

**For and on behalf of
Anuradha Ratnaparkhi and Associates
Chartered Accountants
Firm Registration NO.0023451C**


**Anuradha Ratnaparkhi
Proprietor**

Membership Number: 075412



Date: 03rd November, 2018

Place: Indore